Recombinant alpha-1-microglobulin : A potential treatment for preeclampsia
(2017) In Drug Discovery Today 22(4). p.736-743- Abstract
Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the... (More)
Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the potential to become the first specific therapy for preeclampsia.
(Less)
- author
- Gunnarsson, Rolf ; Åkerström, Bo LU ; Hansson, Stefan R. LU and Gram, Magnus LU
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Drug Discovery Today
- volume
- 22
- issue
- 4
- pages
- 736 - 743
- publisher
- Elsevier
- external identifiers
-
- scopus:85009781743
- pmid:27988357
- ISSN
- 1359-6446
- DOI
- 10.1016/j.drudis.2016.12.005
- language
- English
- LU publication?
- yes
- id
- 4b8c0233-bf05-45e3-901d-ac35a45cb5bd
- date added to LUP
- 2017-03-14 10:11:41
- date last changed
- 2024-09-15 21:49:08
@article{4b8c0233-bf05-45e3-901d-ac35a45cb5bd, abstract = {{<p>Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the potential to become the first specific therapy for preeclampsia.</p>}}, author = {{Gunnarsson, Rolf and Åkerström, Bo and Hansson, Stefan R. and Gram, Magnus}}, issn = {{1359-6446}}, language = {{eng}}, number = {{4}}, pages = {{736--743}}, publisher = {{Elsevier}}, series = {{Drug Discovery Today}}, title = {{Recombinant alpha-1-microglobulin : A potential treatment for preeclampsia}}, url = {{http://dx.doi.org/10.1016/j.drudis.2016.12.005}}, doi = {{10.1016/j.drudis.2016.12.005}}, volume = {{22}}, year = {{2017}}, }